For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm. Moxidectin Oral Gel BP

MoxiRace[™] 2% Equine Oral Gel

COMPOSITION :

Each ml contains Moxidectin BP (Vet)......20 mg Excipients...a.s

INDICATIONS :

MoxiRace 2 % Equine Oral Gel is indicated for treatment of infections caused by moxidectin sensitive strains of: Large strongyles:

Dewormer & Boticide for Horses & Ponies

Strongylus vulgaris (adults and arterial stages) ; Strongylus edentatus (adults and visceral stages) ; Triodontophorus brevicauda (adults) ; Triodontophorus serratus (adults) ; Triodontophorus tenuicollis (adults) Small strongyles (adults and intraluminal larval stages):

Cyathostomum spp. ; Cylicocyclus spp. ; Cylicostephanus spp. ; Cylicodontophorus spp. ; Gyalocephalus spp. Ascarids ·

Parascaris equorum (adult and larval stages) Other species :

Oxyuris equi (adult and larval stages) ; Habronema muscae (adults) ; Gasterophilus intestinalis (L2, L3) ; Gasterophilus nasalis (L2, L3) : Strongyloides westeri (adults) : Trichostrongylus axei

One dose suppresses the production of small strongyle eggs for 84 days. It is indicated for use in horses and ponies, including breeding mares and stallions and foals six months of age and older.

DOSAGE AND ADMINISTRATION : The recommended dose to be used is 0.4 mg moxidectin per kg body weight Give dose corresponding with your horse's weight every 84 days or as directed by your veterinarian.

DIRECTIONS FOR USE :

- It is intended for use only with the dispensing syringe designed for this product.
- · Determine the Accurate weight of the horse/pony
- Remove the cap from the end of the svringe.
- Horse's Mouth must be free of food.
- Insert nozzle of svringe through the interdental space and deposit the paste on back of the tongue by depressing the plunger.
- · Immediately after administration, elevate the head of the horse for a few seconds to ensure the dose is swallowed. · Replace the syringe cap.

ADMINISTRATION : Oral

TARGET SPECIES : Horses and Ponies Six Months of Age and Older.

PHARMACODYNAMIC PROPERTIES :

Pharmacotherapeutic group: Endectocides (milbemycins) ATCvet code: QP54AB02

PHARMACODYNAMICS ·

Moxidectin is a parasiticide active against a wide range of internal and external parasites and is a second generation macrocyclic lactone of the milbemycin family. Moxidectin interacts with GABA and glutamate gated chloride channels. The net effect is to open the chloride channels on the postsynaptic junction to allow the inflow of chloride ions and induce an irreversible resting state. This results in flaccid paralysis and eventual death of parasites exposed to the drug.Moxidectin is effective against benzimidazole resistant strains of cvathostomes.

PHARMACOKINETICS :

Moxidectin is absorbed following oral administration with maximum blood concentrations being achieved 8 hours post application. Bioavailability by the oral route is 40%. The drug is distributed throughout the body tissues but due to its lipophilicity it is selectively concentrated in the fat.

The elimination half life is 28 days. Moxidectin undergoes partial biotransformation by hydroxylation in the body and the only significant route of excretion is the faeces.

WARNING & PRECAUTION :

Special warnings for each target species :

During treatment with the product animals must have free and easy access to drinking water.

Too frequent and repeated use of anthelmintics from the same class over an extended period of time should be avoided as it increases the risk of development of resistance and could ultimately result in ineffective therapy.

Special Precautions For Use :

Special precautions for use in animals :

Do not use the same syringe in more than one animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals :

· Wear gloves during application.

- · Wash the hands thoroughly after use.
- Do not eat, drink or smoke while handling this product.
- Assess bodyweight as accurately as possible before calculating the dosage.
- In case of accidental eve contact, rinse immediately with plenty of water.
- In case of accidental ingestion or eye irritation, seek medical advice and show the package leaflet or label to the physician.

CONTRAINDICATIONS :

Hypersensitivity to any of the Ingredients. Do not administer to animals other than those for which it is indicated

Do not administer to young foals less than 4 months

ADVERSE EFFECTS :

Ataxia, depression, abdominal pain, muscle tremor, flaccid lower lip and swelling of the muzzle could be observed on rare occasions in young animals. These adverse effects are usually transient and disappear spontaneously in most cases.

PREGNANCY AND LACTATION : The veterinary medicinal product has been shown to be safe for use in pregnant and lactating mares

OVERDOSAGE : Adverse reactions may occur at 2 times the recommended dose in foals and 3 times the recommended dose in adult:

WITHDRAWAL PERIOD : Meat & Offal : 32 days after the latest treatment Milk: Not allowed for use in Horses producing milk for human consumption.

STORAGE : Store below 25°C. Discard after 6 months from the date of the first use.

PRESENTATION : 14.4 g Syringe packed in a Primary Carton along with the Pack Insert.

VETERINARY NOT FOR HUMAN USE.

FOR ANIMAL TREATMENT ONLY.

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD. Carefully read the accompanying instructions before use.



Manufactured & Marketed by: VEKO CARE PVT. LTD.

Plot No. E - 48 & 49, MIDC, Ranjangaon, District - Pune, Maharashtra, INDIA. Pin Code : 412220. Customer care : care@vekocare.com TM : Trademark of Veko Care.